Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 2 2Phase 4 1

Status

Completed 17Withdrawn 4Unknown 4Terminated 3Recruiting 2Not yet recruiting 2Active not recruiting 2Suspended 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 222Specimen Handling 194Cisplatin 192Magnetic Resonance Spectroscopy 165Radiotherapy 153Bevacizumab 143Gemcitabine 136Cyclophosphamide 135Drug Therapy 119Capecitabine 118Paclitaxel 116Oxaliplatin 111Nivolumab 105Biopsy 104venetoclax 103tislelizumab 83Rituximab 83durvalumab 82toripalimab 78Fluorouracil 73Etoposide 72Docetaxel 69Dexamethasone 69sintilimab 67Pemetrexed 67atezolizumab 65Radiosurgery 65Azacitidine 63130-nm albumin-bound paclitaxel 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Radiofrequency Ablation × Clear all
NCT04698252 2022-08-08

LARA

Instituto do Cancer do Estado de São Paulo

Phase 2 Recruiting
74 enrolled
Breast

Breast Neoplasms

NCT04150744 2020-07-08

RFA Plus Carrizumab vs Carrizumab Alone for HCC

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡